Search hospitals

>

Nebraska

>

Omaha

University of Nebraska Medical Center

Claim this profile

Omaha, Nebraska 68105

Global Leader in Cancer

Global Leader in Lymphoma

Conducts research for Non-Hodgkin's Lymphoma

Conducts research for Leukemia

Conducts research for Lung Cancer

1232 reported clinical trials

94 medical researchers

Photo of University of Nebraska Medical Center in OmahaPhoto of University of Nebraska Medical Center in Omaha

Summary

University of Nebraska Medical Center is a medical facility located in Omaha, Nebraska. This center is recognized for care of Cancer, Lymphoma, Non-Hodgkin's Lymphoma, Leukemia, Lung Cancer and other specialties. University of Nebraska Medical Center is involved with conducting 1,232 clinical trials across 1,402 conditions. There are 94 research doctors associated with this hospital, such as Jill C. Beck, Minnie Abromowitch, Jonathan Thompson, MD, and Matthew Lunning, DO.

Area of expertise

1

Cancer

Global Leader

University of Nebraska Medical Center has run 109 trials for Cancer. Some of their research focus areas include:

Stage IV
Stage III
Stage I
2

Lymphoma

Global Leader

University of Nebraska Medical Center has run 105 trials for Lymphoma. Some of their research focus areas include:

Stage IV
Stage III
Stage II

Top PIs

Clinical Trials running at University of Nebraska Medical Center

Breast Cancer

Skin Cancer

Lung Cancer

Cancer

Brain Tumor

Breast cancer

Pancreatic Cancer

Prostate Cancer

Testicular cancer

Multiple Myeloma

Image of trial facility.

Radiation Therapy

for Brain Metastasis

This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. FSRS delivers a high dose of radiation to the tumor over 3 treatments. SRS is a type of external radiation therapy that uses special equipment to position the patient and precisely give a single large dose of radiation to a tumor. FSRS may be more effective compared to SRS in treating patients with cancer that has spread to the brain.

Recruiting

2 awards

Phase 3

12 criteria

Image of trial facility.

Low Dose Tamoxifen

for Breast Cancer

This phase III trial compares the effect of low dose tamoxifen to usual hormonal therapy, including aromatase inhibitors, in treating post-menopausal women with hormone positive, HER2 negative early stage breast cancer. Tamoxifen is in a class of medications known as antiestrogens. It blocks the activity of estrogen (a female hormone) in the breast. This may stop the growth of some breast tumors that need estrogen to grow. Aromatase inhibitors, such as anastrozole, letrozole, and exemestane, prevent the formation of estradiol, a female hormone, by interfering with an aromatase enzyme. Aromatase inhibitors are used as a type of hormone therapy to treat postmenopausal women with hormone-dependent breast cancer. Giving low dose tamoxifen may be more effective compared to usual hormone therapy in treating post-menopausal women with hormone-positive, HER2 negative early stage breast cancer.

Recruiting

2 awards

Phase 3

8 criteria

Image of trial facility.

Omitting Radiation Therapy

for Breast Cancer

The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.

Recruiting

2 awards

Phase 3

19 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at University of Nebraska Medical Center?

Where is University of Nebraska Medical Center located?

Who should I call to ask about financial aid or insurance network?

What insurance does University of Nebraska Medical Center accept?

What awards or recognition has University of Nebraska Medical Center received?